IBCSG

Web Cast of Landmark, Independent Trial Data from Major Breast Cancer Meeting

    St. Gallen, Switzerland (ots/PRNewswire) -

    - Promising News for Breast Cancer Patients

    - Web Cast Briefing Available at http://www.ibcsg.org/index.shtm

@@start.t1@@        WHAT:        BIG 1-98: First results and implications. A landmark,
                        independent study found that letrozole, a leading aromatase
                        inhibitor also known as Femara, demonstrated better efficacy
                        in reducing the risk of recurrence for breast cancer compared
                        with the current standard of care, tamoxifen.
                        Significant findings include:
                        - Letrozole reduced the risk of breast cancer recurrence by
                          19% compared with tamoxifen
                        - Letrozole significantly prolonged disease free survival
                          compared with tamoxifen
                        - Letrozole reduced the risk of breast cancer mestasis by 27%
                          compared with the reduction offered by tamoxifen
                        This Web cast offers a presentation of the BIG 1-98 trial
                        results presented at the Primary Therapy of Early Breast
                        Cancer 9th International Conference in St. Gallen, Switzerland
                        and an understanding of what the trial results
                        mean for patients.
                        BIG 1-98 is an independent Phase III, randomized, double-
                        blind, controlled clinical trial of more than 8,000
                        postmenopausal women with early breast cancer
                        from 27 countries
        WHEN:        1:05 pm ET / 7:05 pm. CET, Wednesday, 26 January
        WHERE:      Click on the following link and view the Web cast data
                        presentation: http://www.ibcsg.org/index.shtm
        WHO:         PD Beat Thurlimann, M.D., Scientific Secretary General,
                        Primary Therapy of Early Breast Cancer, Head of the Senology
                        Center of Eastern Switzerland, Kantonsspital St. Gallen,
                        Presentation of the BIG 1-98 Trial Results
        CONTACTS: For questions or to arrange an interview with PD Beat
                        Thurlimann, please contact:
                        Rum Ekhtiar                            Nadia Munarini, PhD
                        Ruder Finn                              IBCSG
                        Tel. +1-212-593-5821              Tel. +41-31-389-92-27
                        ekhtiarr@ruderfinn.com          nadia.munarini@ibcsg.org@@end@@

    Web Site: http://www.ibcsg.org/index.shtm

ots Originaltext: IBCSG
Im Internet recherchierbar: http://www.newsaktuell.ch

Contact:
Nadia Munarini, PhD, IBCSG, +41-31-389-92-27, or
nadia.munarini@ibcsg.org; Rum Ekhtiar of Ruder Finn, +1-212-593-5821,
or ekhtiarr@ruderfinn.com, for IBCSG



Weitere Meldungen: IBCSG

Das könnte Sie auch interessieren: